Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SurModics, a provider of drug delivery and surface modification technologies to the healthcare industry, has reported revenues of $15.17m for the first quarter ended 31 December 2010, compared to $17.38m for the comparable period in 2009.
Subscribe to our email newsletter
Net income was $377,000 for the first quarter 2010, or $0.02 loss per diluted share, compared to $1.92m, or $0.11 per diluted share, for the comparable period in 2009.
SurModics‘ income from operations was $720,000, compared to $2.77m for the comparable period in 2009.
SurModics’ president and CEO Gary Maharaj said by refocusing their efforts within a well-defined core, they have an opportunity to build upon their strengths to create sustainable, long-term growth and shareholder value.
"During the coming months, I will be working diligently with the management team and the Board to develop our strategic plan, and I look forward to sharing more details as they emerge," Maharaj said.